Client case · buccal delivery · engineering dose check
Dose capacity of a buccal film: does the therapeutic dose fit
A client wanted to move an active substance into a buccal film, assuming the daily dose would "just pour" into one or two films. We tested that with a dose-capacity calculation — before any formulation cycles. The client and the substance are under NDA; we show the premise, the method and the real limit of the form.
The case in brief
The client was considering moving a water-soluble active substance into a buccal (orodispersible) film, on the assumption that the target daily dose would fit comfortably into one or two films. We ran an engineering check of the form's dose capacity. The answer is negative but unambiguous: the film is strong as a split-dose, maintenance form for 1–2 intakes, not as the sole carrier of the entire daily dose.
- The active-substance fraction in a film usually does not exceed 30–40% w/w — a physical ceiling that formulation tuning cannot remove.
- A realistic working load for a single film is 20–30 mg; the commercial ceiling is about 50 mg.
- At a target buccal daily dose of several hundred mg, that means 2 to 20 films a day.
The starting point
The client was developing a product based on a buccal (orodispersible) film — an ODF — with a water-soluble active substance. The appeal of the form is clear: the film dissolves in the mouth, part of the substance is absorbed through the mucosa and partly bypasses the "first pass" — for this class of substances that is decisive, because with ordinary oral intake high oral doses produced no rise in plasma owing to breakdown in the gastrointestinal tract, whereas the transmucosal route, per review data, gives severalfold higher bioavailability. But the client's initial assumption was a product one, not an engineering one: since the buccal route is more effective, the target daily dose can be "just poured" into a film. Quantitatively the client had not checked the main thing — how much substance physically fits into a single film, and how many films a day a therapeutic dose would require.
What the analysis showed: the capacity of one film
A film's capacity is capped from above by the mass of the polymer matrix. The active-substance fraction usually does not exceed 30–40% w/w: at a higher load, brittleness and dissolution time rise and dose uniformity suffers. Hence a hard physical ceiling on the mass of substance in a single film — one that formulation tuning cannot lift. Realistic loading of a single film by type, at an active-substance fraction of up to 30–40% w/w:
| Film type | Dose per film | Feasibility | Comment |
|---|---|---|---|
| Standard ODF (~2×3 cm, ~20% w/w) | 20–30 mg | easy | A realistic working load; the substance's good solubility makes a high w/w easier. |
| Large / dense (6–10 cm², ~30% w/w) | 30–50 mg | feasible | Benchmark — the riluzole ODF Exservan (50 mg, FDA 2019): the record commercial loading limit for an ODF. |
| Multilayer (2–3 active layers) | 50–100 mg | hard | Dissolution time, dose-non-uniformity risk and cost all rise; separate validation is required. |
How many films a day
Next, the target daily dose is converted into a number of films. The scientifically grounded target range for the buccal / sublingual route is 50–200 mg per dose, 1–3 times a day. Setting these doses against a film's capacity (realistic load 20 mg · high 30 mg · maximum 50 mg per film) gives the following picture:
| Daily dose, mg | 20 mg/film (realistic) | 30 mg/film (high load) | 50 mg/film (maximum) |
|---|---|---|---|
| 100 | 5 | 4 | 2 |
| 200 | 10 | 7 | 4 |
| 250 | 13 | 9 | 5 |
| 300 | 15 | 10 | 6 |
| 400 | 20 | 14 | 8 |
| 500 | 25 | 17 | 10 |
Assembling a full upper-range daily dose (250–400 mg) entirely "in films" is impractical — it would take 5 to 20 units a day. Only the lower doses fit a convenient regimen (1–2 films a day). At the same time, thanks to better buccal absorption, a 30–50 mg film can be therapeutically equivalent to an oral 250–500 mg/day — that is, the form genuinely wins as a split form, not as a carrier of the whole dose at once.
The result
The project got a quantitative limit on the form before entering formulation and stability cycles. Product positioning shifted from "a film instead of the whole daily dose" to "a film as a convenient buccal form for a maintenance dose" — where the advantage of mucosal absorption genuinely works and the number of units a day stays acceptable. The client also received a ready planning tool: a "target dose → number of films" conversion table for three loading levels, which can be applied to any chosen dose.
The takeaway
A buccal film with this substance is both possible and sensible — but as a maintenance, split-dose form for 1–2 intakes a day, not as the sole carrier of the entire daily dose. The realistic working load is 20–30 mg per film, and the commercial ODF ceiling is about 50 mg. A full upper-range daily dose in films is impractical.
Why this is value, not criticism
The temptation is to read "the full dose won't fit in a film" as abandoning the idea. In fact this is exactly the result the check is for: a quantitative limit on the form, uncovered by calculation in a matter of days, rather than discovered after a formulation has already been fitted to an inflated dose, polymer ordered and stability cycles run. The capacity calculation did not close the project — it redirected it toward a workable scenario and removed the risk of building a product around an unachievable dose in a single film. A cheap check at the idea stage replaced an expensive mistake at the formulation and scale-up stage.
Caveats and data status
The film-capacity estimates (20–30 mg realistic load, about 50 mg commercial ODF limit with reference to the riluzole ODF Exservan, FDA 2019, active-substance fraction ≤ 30–40% w/w) are engineering benchmarks from the orodispersible-film literature and commercial analogues, not the result of bench casting of the client's specific formulation. The "dose → number of films" conversion table is a direct arithmetic calculation from these loading levels. The dose ranges (buccal 50–200 mg per dose, 1–3 times a day) are extrapolated from the mechanistically closest sublingual forms: no directly published clinical or pharmacokinetic studies of a buccal film with this exact substance could be found. The estimate rests on 41 dose findings from peer-reviewed sources (with PMID/DOI/NCT identifiers). The client, the active substance, the therapeutic target and the project details are not disclosed under a confidentiality agreement.
Check the dose capacity of a form for your substance?
Message us — we'll show the method and work out how much of your daily dose actually fits into a film, before you enter formulation and stability cycles.
The technical statements are based on an internal engineering-pharmacokinetic assessment by gxplaunch on dose feasibility in a buccal (orodispersible) film (2026), with the dose data verified against peer-reviewed sources. This material is informational: it is not medical advice, a regulatory opinion or investment advice. The conclusions concern the dose capacity of orodispersible / buccal films in general; applying them to a specific substance requires separate formulation, stability and clinical verification. The case is anonymized; the client, the substance and the project details are under NDA.